Featured Research

from universities, journals, and other organizations

Boy or girl? Australians think we shouldn't choose

Date:
December 22, 2010
Source:
University of Melbourne
Summary:
Most Australians do not approve of IVF or abortion for sex-selection purposes, and most do not think a hypothetical blue or pink pill to select the sex of a child should be legal, a new study has found.

Most Australians do not approve of IVF (in vitro fertilization) or abortion for sex-selection purposes, and most do not think a hypothetical blue or pink pill to select the sex of a child should be legal, a new study has found.

The study, led by Dr. Rebecca Kippen from the School of Population Health at the University of Melbourne, analyzed responses from more than 2,500 people participating in the Australian Survey of Social Attitudes, combined with a series of in-depth parental interviews.

The survey found that 69 per cent of respondents disapproved the use of IVF for sex selection, with the disapproval rate increasing to 80 per cent for sex-selective abortions. The legalization of hypothetical blue and pink pills for sex selection was supported by only 11 per cent of respondents. Dr. Kippen said similar responses resulted from the in-depth interviews carried out with parents.

"Opposition to these technologies was grounded in three major concerns: the potential for distorted sex ratios; that sex selection can be an expression of gender bias; and a concern about 'designer infants' being created, when parents should be happy with a healthy baby," she said.

The findings, published online in Fertility and Sterility in December 2010, and co-authored by Dr. Ann Evans and Dr. Edith Gray from the Australian Demographic and Social Research Institute at the Australian National University, contrast with previous behavioral and attitudinal research that shows Australian parents want a balanced family, that is, a family with at least one son and one daughter.

The study is particularly timely given that the National Health and Medical Research Council (NHMRC) is due to review the ban on sex selection in 2011, and has called for community discussion of issues surrounding sex selection.

The ban began in 2004, with the introduction of the NHMRC's Ethical Guidelines on the Use of Assisted Reproductive Technology in Clinical Practice and Research. These guidelines -- which have the force of law -- state that ''sex selection (by whatever means) must not be undertaken except to reduce the risk of transmission of a serious genetic condition.''


Story Source:

The above story is based on materials provided by University of Melbourne. Note: Materials may be edited for content and length.


Journal Reference:

  1. Rebecca Kippen, Ann Evans, Edith Gray. Australian attitudes toward sex-selection technology. Fertility and Sterility, 2010; DOI: 10.1016/j.fertnstert.2010.11.050

Cite This Page:

University of Melbourne. "Boy or girl? Australians think we shouldn't choose." ScienceDaily. ScienceDaily, 22 December 2010. <www.sciencedaily.com/releases/2010/12/101222093206.htm>.
University of Melbourne. (2010, December 22). Boy or girl? Australians think we shouldn't choose. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/12/101222093206.htm
University of Melbourne. "Boy or girl? Australians think we shouldn't choose." ScienceDaily. www.sciencedaily.com/releases/2010/12/101222093206.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins